TUESDAY 20 July 2021 (HealthDay News) – The overall global age-standardized prevalence of dementia in young adults (YOD), in which symptoms begin before age 65, is 119.0 per 100,000 population, according to a systematic review and meta-analysis online published July 19 in JAMA Neurology,
Stevie Hendricks, from the University of Maastricht in the Netherlands, and colleagues investigated the worldwide prevalence of YOD. The systematic review included 95 unique studies, of which 74 with 2,760,379 unique patients were included in meta-analyzes of five-year age band.
The researchers observed an increase in the age-standardized prevalence estimates from 1.1 to 77.4 per 100,000 population among those aged 30 to 34 years and for those aged 60 to 64 years, respectively. In the age range of 30 to 64 years, the overall global standardized prevalence was 119.0 per 100,000, corresponding to 3.9 million people aged 30 to 64 living with YOD worldwide. In subgroup analyzes, the prevalence was equal for men and women (rough estimates, 216.5 and 293.1 per 100,000 population, respectively), but prevalence was lower in upper and upper middle and lower middle-income countries (rough estimates, 663.9 against 1,873.6 and 764.2 per 100,000 population, respectively).
“This systematic review and meta-analysis estimates the age-standardized prevalence at 119.0 per 100,000 population worldwide. Although this is higher than previously thought, it is likely an underestimation due to lack of high quality data,” the authors write. “This should raise awareness for health care policy makers and professionals to organize more and better care for this subgroup of individuals with dementia.”
One author discloses financial ties to the biopharmaceutical sector; one author reported ownership of a dementia screening test.
Abstract / Full text (subscription or payment may be required)
Editorial (subscription or payment may be required)